Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
35
EVFM Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
-4.11%
Day range:
$0.0095 - $0.0106
52-week range:
$0.0060 - $0.0200
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.93x
P/B ratio:
--
Volume:
661.4K
Avg. volume:
218.5K
1-year change:
5.53%
Market cap:
$1.3M
Revenue:
$19.4M
EPS (TTM):
-$0.06
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Evofem Biosciences, Inc. has 2184366.02% upside to fair value with a price target of -- per share.
EVFM vs. S&P 500
-
Over the past 5 trading days, Evofem Biosciences, Inc. has underperformed the S&P 500 by -14.26% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Evofem Biosciences, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Evofem Biosciences, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Evofem Biosciences, Inc. reported revenues of $5M.
Earnings Growth
-
Evofem Biosciences, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Evofem Biosciences, Inc. reported earnings per share of -$0.01.
Enterprise value:
57.5M
EV / Invested capital:
-3.19x
Price / LTM sales:
0.93x
EV / EBIT:
--
EV / Revenue:
3.24x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-12.97x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$13.5M
Return On Assets:
-30.6%
Net Income Margin (TTM):
-30.66%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-19.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $13.6M | $17.1M | $17.7M | $4.5M | $5M | |
| Gross Profit | $4.7M | $13.3M | $13.5M | $3.3M | $4M | |
| Operating Income | -$26.1M | -$10.1M | -$2.2M | -$2.4M | -$982K | |
| EBITDA | -$23.2M | -$9.6M | -$1.3M | -$2.1M | -$864K | |
| Diluted EPS | -$18.84 | -$0.91 | -$0.06 | -$0.02 | -$0.01 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $54.9M | $31.8M | $11.5M | $8.6M | $7.9M | |
| Total Assets | $67.4M | $42.3M | $13.3M | $23.9M | $13.8M | |
| Current Liabilities | $94.7M | $116.7M | $67.9M | $76.3M | $78.2M | |
| Total Liabilities | $126.3M | $120.3M | $67.9M | $90.1M | $84M | |
| Total Equity | -$58.8M | -$78M | -$54.6M | -$66.1M | -$70.2M | |
| Total Debt | $100.2M | $81.1M | $41.1M | $44.4M | $50.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.3M | -$1.6M | -$4.4M | -$459K | $336K | |
| Cash From Investing | -$39K | -$523K | -$105K | -$509K | -- | |
| Cash From Financing | $5.9M | $2.5M | $4.7M | $998K | -$244K | |
| Free Cash Flow | -$15.4M | -$1.7M | -$4.4M | -$459K | $336K | |
EVFM
Sector
Market Cap
$1.3M
$27.9M
Price % of 52-Week High
51.5%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-32.67%
-1.49%
1-Year Price Total Return
5.53%
-16.66%
Beta (5-Year)
-1.277
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0109
200-day SMA
Buy
Level
$0.0100
Bollinger Bands (100)
Sell
Level
0.0108 - 0.0108
Chaikin Money Flow
Sell
Level
-10.6M
20-day SMA
Sell
Level
$0.0105
Relative Strength Index (RSI14)
Sell
Level
49.0711
ADX Line
Buy
Level
33.4073
Williams %R
Neutral
Level
-73.3333
50-day SMA
Sell
Level
$0.0104
MACD (12, 26)
Buy
Level
0.0001
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Sell
Level
-1.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-56.2033)
Sell
CA Score
(Annual)
Level (-21.1038)
Sell
Beneish M-Score
(Annual)
Level (46.1243)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (24.2653)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes products to women's sexual and reproductive health. Its product includes Phexxi (lactic acid, citric acid and potassium bitartrate), a hormone-free vaginal gel and EVO100, an investigational drug, which is used for urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. The company was founded in 2007 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, EVFM has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EVFM average analyst price target in the past 3 months is --.
-
Where Will Evofem Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Evofem Biosciences, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Evofem Biosciences, Inc.?
Analysts are divided on their view about Evofem Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Evofem Biosciences, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Evofem Biosciences, Inc.'s Price Target?
The price target for Evofem Biosciences, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EVFM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Evofem Biosciences, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of EVFM?
You can purchase shares of Evofem Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Evofem Biosciences, Inc. shares.
-
What Is The Evofem Biosciences, Inc. Share Price Today?
Evofem Biosciences, Inc. was last trading at $0.0100 per share. This represents the most recent stock quote for Evofem Biosciences, Inc.. Yesterday, Evofem Biosciences, Inc. closed at $0.0103 per share.
-
How To Buy Evofem Biosciences, Inc. Stock Online?
In order to purchase Evofem Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get EVFM Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
EVFM
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
--
1.81x
Price / LTM sales
0.93x
1.58x
Growth Metrics
EVFM
Sector
Revenue growth
10.14%
4.62%
Earnings growth
43.09%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.21
Profitability
EVFM
Sector
Profitability FY 2024
$14.9M
$3.6M
Return on invested capital
--
-31.87%
Return on assets
-30.6%
-28.18%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Aug
2
Next Earnings Date
Dec
21
Estimated Next Earnings Date
Mar
22
Balance Sheet
EVFM
Sector
Total cash
$840K
$26.4M
Short term investments
--
$25.7M
Total assets
$23.8M
$76.9M
Long term debt
$50.7M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
